#########
Volume 12, Number 29
Monday, July 16, 2012
#########


JULY IS EYE INJURY PREVENTION MONTH




In this issue: (click heading to view article)
#########
######### Myopia Progression and Foveal mfERG Response in Children
#########
######### Relationship Between Visual Impairment, Age-Related Eye Diseases and Cognitive Function
#########
######### Response of the Posterior Corneal Surface to Myopic LASIK with Different Ablation Depths
#########
######### Impact of Low Vision Rehabilitation in Diabetic Eye Disease
#########
######### Briefly

 

 

http://ecatalog.alcon.com/PI/Nevanac_us_en.pdf





Myopia Progression and Foveal mfERG Response in Children

In Hong Kong, the authors of the following study examined the changes in retinal electrophysiology in children during myopia progression over a 1-year period.

They recruited 26 children aged from 9 to 13 years for the global flash multifocal electroretinogram (mfERG) measured at 49% and 96% contrasts, in two visits one year apart. They analyzed and compared the amplitudes and implicit times of both direct component (DC) and induced component (IC) measured at these two visits and used Pearson's correlation to study the association between the changes of mfERG response and myopia progression over the test period.

The study authors noted that myopia increased by –0.48 ± 0.32 D (p<0.001) over the year, with 24 of 26 children becoming more myopic (range=0.00 ~–1.38D); axial length increased by 0.25 ± 0.11 mm (p<0.001) over the year. They found that the increased myopia was highly correlated with increase in axial length (r=–0.70; p<0.001) and that the central DC and IC amplitudes at 49% contrast reduced significantly as myopia progressed and the paracentral implicit times of these two components were reduced considerably. However, the high-contrast responses were virtually unaffected.

The authors' findings suggest that the inner retinal functions in the central retina, with some involvement of the paracentral region, were decreased as myopia progressed.

SOURCE: Ho WC, Kee CS, Chan HH. Myopia progression in children is linked with reduced foveal mfERG response. Invest Ophthalmol Vis Sci. 2012;July 3 [Epub ahead of print].










Relationship Between Visual Impairment, Age-Related Eye Diseases and Cognitive Function

To describe the associations of visual impairment and major age-related eye diseases with cognitive function in an older Asian population, researchers conducted this population-based, cross-sectional study of 1,179 participants aged 60 to 80 years from the Singapore Malay Eye study.

They measured visual acuity using the logMAR vision chart and graded cataract and age-related macular degeneration using the Wisconsin Cataract Grading System and the Wisconsin Age-Related Maculopathy Grading System, respectively. Glaucoma was diagnosed using the International Society Geographical and Epidemiological Ophthalmology criteria and diabetic retinopathy was graded using the modified Airlie House classification system. Additionally, cognitive dysfunction was defined as a locally validated Abbreviated Mental Test using education-based cutoff scores.

After adjusting for age, sex, education level, income, and type of housing, the researchers found that persons with visual impairment before refractive correction (odds ratio [OR]=2.59; 95% CI, 1.89–3.56) or after refractive correction (OR=1.96; 95% CI, 1.27–3.02) and those with visual impairment due to cataract (OR=2.75; 95% CI, 1.25–5.63) were more likely to have cognitive dysfunction. They reported that only moderate to severe diabetic retinopathy was independently associated with cognitive dysfunction (OR=5.57; 95% CI, 1.56–19.91) after controlling for concurrent age-related eye diseases. They observed no significant independent associations between cataract, age-related macular degeneration, or glaucoma and cognitive dysfunction.

In conclusion, older persons with visual impairment, particularly those with visual impairment due to cataract, were more likely to have cognitive dysfunction. Furthermore, among the major age-related eye diseases, only diabetic retinopathy was associated with cognitive dysfunction.

SOURCE: Ong SY, Cheung CY, Li X, et al. Visual impairment, age-related eye diseases, and cognitive function: the Singapore Malay Eye Study. Arch Ophthalmol. 2012;130(7):895–900.



http://www.revophth.com/ResFellowEdu2012






Response of the Posterior Corneal Surface to Myopic LASIK with Different Ablation Depths

The following cohort study evaluated the posterior corneal surface response at a very early stage following myopic laser in-situ keratomileusis (LASIK) with different ablation depths and observed posterior steepening and a shift toward prolateness of the posterior surface very early after myopic LASIK, with a tendency to return toward the preoperative level between 1 month and 3 months.

Healthy myopic eyes were divided based on the achieved ablation depth as follows: Group 1, >100 µm; Group 2, between 50 µm and 99 µm; Group 3, less than 50 µm. Posterior eccentricity and central (0.0 mm to 4.0 mm), paracentral (4.0 mm to 7.0 mm), and peripheral (7.0 mm to 10.0 mm) posterior corneal curvatures were measured with the Galilei system preoperatively and postoperatively after 1 day, 1 week, and 1 and 3 months.

A total of 80 eyes were evaluated. Posterior surface steepening and a shift toward prolateness occurred in all groups, with a peak within the first week before returning toward the original level after 1 month. The maximum change in the central posterior cornea occurred after 1 day in Group 1 and reached –0.106 D. This change was statistically significant (p=.03) and statistically greater than the change in Group 2 (mean –0.042 D; p=0.02) and Group 3 (mean –0.026 D; p<.01). This change was not significant after 3 months (p=.5). The degree of change was related to the amount of anterior tissue severed.

SOURCE: Smadja D, Santhiago MR, Mello GR, et al. Response of the posterior corneal surface to myopic laser in situ keratomileusis with different ablation depths. J Cataract Refract Surg. 2012;38(7):1222–1231.

 



http://www.revophth.com/saos2012






Impact of Low Vision Rehabilitation in Diabetic Eye Disease

The following study sought to determine whether conjunctival ultraviolet autofluorescence (UVAF), a biomarker of outdoor light exposure, is associated with myopia.

Current research highlights a rising incidence of diabetes and its complications. Diabetic retinopathy is the leading cause of blindness within the working-age population of the United Kingdom. Increasing severity of retinopathy is associated with reduced visual function and participation in daily living. Only 8% of those referred to Moorfields Eye Hospital's low vision clinic have diabetic eye disease, a value less than prevalence figures for diabetes would predict. The lack of evidence for effectiveness of low vision intervention in this patient group could be responsible. Therefore, in line with CONSORT guidance, London investigators present the methodology of the first randomized controlled trial to quantify the effect of low vision rehabilitation on people with diabetic eye disease.

They recruited 100 participants into four retinopathy severity groups based on their diagnosis according to the English National Screening Programme Grading Protocol and randomized them to either immediate intervention (1–2 weeks after enrolment) or delayed (control) intervention (3 months after enrolment). Intervention was a standard low vision assessment performed in a hospital clinic. The Activity Inventory (AI), was administered to all participants by telephone within 1 week of enrollment (before any intervention) and repeated at 3 and 6 months.

According to the study investigators, 100 participants (Type 1: 28, Type 2: 72; male: 62, female 38) have been recruited. They noted that median habitual distance acuity was 0.19 logMAR (6/9, 20/30), with an interquartile range of 0.06–0.30 logMAR (6/7.5–6/12, 20/25–20/40). AI responses were scored by Rasch analysis, providing a measure of visual ability. Median baseline visual ability was 1.64 logits, with an interquartile range of 0.60–3.75 logits. Difference in mean change in visual ability between intervention groups will be assessed 3 months (primary outcome) and 6 months (secondary outcome) after enrolment.

To conclude, this is the first randomized controlled trial investigating the effectiveness of low vision rehabilitation for people with diabetic eye disease. With recruitment already complete, it is hoped this work will be the first step in guiding referral criteria for those with diabetic eye disease into the low vision service.

SOURCE: Dunbar HM, Crossland MD, Bunce C, et al. The effect of low vision rehabilitation in diabetic eye disease: a randomized controlled trial protocol. Ophthalmic Physiol Opt. 2012;32(4):282–293.




http://www.revophth.com/avtt2012







  • PATIENT ENROLLMENT COMPLETE FOR PHASE 3 CLINICAL TRIAL OF LUVENIQ. Lux Biosciences, Inc. has completed patient enrollment in its Phase 3 clinical trial of Luveniq (oral voclosporin) for the treatment of non-infectious uveitis. The study is a six-month, randomized, multi-center, double-masked, controlled trial to evaluate the efficacy and safety of Luveniq for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye and includes 155 patients at 56 sites across North America, Europe and Brazil. The primary endpoint of the trial is the change from baseline in vitreous haze at 12 weeks or at the time of treatment failure, if earlier. Lux Biosciences anticipates that data from the Phase 3 study will be available early in the first quarter of 2013 and, if positive, will address the FDA's request for additional clinical information as part of the Complete Response letter regarding the New Drug Application (NDA) for Luveniq issued in August 2010. The company also expects the trial results, if positive, to support a resubmission of the NDA under priority review early in 2013 and to support a regulatory filing to the European Medicines Agency for Luveniq. Additional information is available at www.luxbio.com.
  • R-TECH UENO TO COLLABORATE ON NEW DRUG DELIVERY SYSTEM FOR UNOPROSTONE. R-Tech Ueno will conduct a collaborative study with Tohoku University, a national university corporation, to develop a drug delivery system for Isopropyl Unoprostone, a compound made by R-Tech Ueno, using a patent pending sustained drug delivery system device. Unlike conventional devices that are inserted into the eye, this new device is a minimally invasive transscleral drug delivery system that is attached to the sclera and does not require vitreous surgery. R-Tech Ueno considers that if the unoprostone drug delivery system is realized, the treatment with unoprostone will become feasible in patients with retinitis pigmentosa in whom frequent instillation is difficult. Click here for more details.
  • EYEMAGINATIONS' SOFTWARE UPDATE FOR LUMA FEATURES NEW EYECARE TOPICS. Eyemaginations, Inc. has announced its latest software update for LUMA, the comprehensive patient education and marketing software platform for healthcare professionals. The company says that LUMA v1.9.5 features a wide variety of new eyecare topics, including Tear Osmolarity Testing, Exfoliation Glaucoma, and Mixing Premium IOLs. With LUMA, doctors can ensure that patients understand their conditions and treatments and the practice can also market premium products and services to drive revenue while saving time and increasing productivity. Additionally, LUMA v1.9.5 includes a new series of silent waiting room segments designed to provide specific messaging and call-to-action language for patient marketing. Further information on LUMA's new software update can be found at www.eyemaginations.com.
  • TOPCON MEDICAL UNVEILS NEW COMPUTERIZED LENSMETER. Topcon Medical Systems has commercially introduced the new CL-300 Computerized Lensmeter to the U.S. and Latin American markets. The CL-300 is the latest generation of Topcon computerized lensmeters and its compact, ergonomic design and intuitive touch screen panel ensure that eyecare practitioners and technicians obtain comprehensive data and accurate measurements easily and quickly. According to Topcon, the CL-300 incorporates many of the features from previous Topcon lensmeters, but adds several new features, including a new UV transmittance measurement function that provides reliable measurement results for eyeglasses and sunglasses in the range of 0% to 100%. Additionally, the new multifocal lens measurement ensures that mono- and multifocal lenses can be easily measures, and the CL-300 also features automatic detection for single and progressive lenses. Learn more at www.topconmedical.com.
  • NEW CORPORATE STRATEGY MEANS MANY CHANGES IN STORE FOR QLT. Jason M. Aryeh, chairmen of the recently appointed Board of Directors of QLT Inc., on behalf of the board, issued a letter to QLT's shareholders outlining a new corporate strategy and the rationale for its implementation, which relates to concerns of the company's shareholders. The letter states that the board has unanimously determined to take actions that include: retaining Goldman Sachs to explore the sale or spin-out of QLT's Punctal Plug Delivery System (PPDS) and to determine whether the company should retain or explore opportunities to partner or sell its Visudyne business; reducing the company's personnel by 146 employees over the coming months; appointing a new member to the board of Directors and welcoming Argot Partners as its new public relations and investor relations firm. Additionally, QLT's President and CEO, Robert Butchofsky, will also be leaving the company. Click here to learn more and read the actual letter.
  • ANNUAL SUMMER SYMPOSIUM PAIRS OWL WITH WIO. Ophthalmic Women Leaders (OWL) has announced its participation at the upcoming Women in Ophthalmology (WIO) Summer Symposium August 9-12 in Williamsburg, Va. OWL will host a special session entitled “You CAN Get there from Here,” which will be broken into three sections: Developing Your Leadership Position; Demystifying the Path to the Podium; and Negotiating Your Next Step. Event registration for the Summer Symposium will remain available through August 2. For additional information, visit www.wioonline.org.

 

http://www.revophth.com






Review of Ophthalmology® Online is published by the Professional Publications Division of Jobson Medical Information LLC (JMI), 11 Campus Boulevard, Newtown Square, PA 19073.

To subscribe to other JMI newsletters or to manage your subscription, click here.

To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address.

To ensure delivery, please be sure to add reviewophth@jobsonmail.com to your address book or safe senders list.

Click here if you do not want to receive future emails from Review of Ophthalmology Online.

Advertising: For information on advertising in this e-mail newsletter or other creative advertising opportunities with Review of Ophthalmology, please contact publisher Rick Bay, or sales managers James Henne or Michele Barrett.

News: To submit news or contact the editor, send an e-mail, or FAX your news to 610.492.1049